Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

98 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00390221

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Olomouc, Czechia
  • Research Site Pilsen, Czechia
  • Research Site Teplice, Czechia
View all 56 locations
View Trial Details
Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

NCT01884935

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Cefalù, Italy
  • Research Site Gallarate, Italy
  • Research Site Milan, Italy
  • Research Site Padua, Italy
View Trial Details
Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

NCT02205489

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Investigational Site Number 056002 Bruges, Belgium
  • Investigational Site Number 056001 Brussels, Belgium
  • Investigational Site Number 250009 Dijon, France
  • Investigational Site Number 250005 Lille, France
View all 20 locations
View Trial Details
Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Cullman, Alabama, United States
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
View all 43 locations
View Trial Details
Completed

Extension Study of MT-1303

NCT01890655

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site City Name, Belgium
  • Research Site City Name, Bulgaria
  • Research Site City Name, Canada
  • Research Site City Name, Croatia
View all 17 locations
View Trial Details
Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

NCT01416155

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Chiba, Japan
  • Research Site Fukuoka, Japan
  • Research Site Hiroshima, Japan
  • Research Site Sapporo, Hokkaido, Japan
View all 22 locations
View Trial Details
Completed

Safety and Tolerability of Glatiramer Acetate

NCT01874145

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Teva Investigational Site 10706 Cullman, Alabama, United States
  • Teva Investigational Site 10719 Gilbert, Arizona, United States
  • Teva Investigational Site 10720 Phoenix, Arizona, United States
  • Teva Investigational Site 10727 Fresno, California, United States
View all 35 locations
View Trial Details

Related conditions